The Finnish veterinary medicine company Vetcare Group is updating its Board and launching a new Advisory Board
Kalevi Heinonen will continue as the Chairman of the new Board, Thomas Hoyer has been appointed Deputy Chairman and Saara Hakkarainen as a member of the Board. The new line-up was approved by Vetcare’s Annual General Meeting in May and will be operational with immediate effect.
At the same time, the company will launch an Advisory Board to support its growth in international exports. The new Advisory Board consists of angel investor Stefanie Kiki Brandt-Tallqvist, Board professional Kalle Ruuskanen and pharmaceutical industry consultant Veli-Matti Riipinen.
As a family-owned company, the members of Vetcare’s Board of Directors are nominated by the founding family.
“In the spring, we obtained marketing authorisations in the EU and the United States for the canine sedative and analgesic we developed from the original molecule. Therefore, we are now turning our attention even more towards international growth. We are the market leader in the domestic veterinary medicine market and are currently reorganising our structures to meet the international competitive field,” says Olli Kuussaari, CEO of Vetcare Group.
Vetcare invests a significant portion of its annual revenue in product development and research in the veterinary medicine industry. The now-authorised sedative was discovered in a study by the University of Helsinki’s Faculty of Veterinary Medicine in the beginning of 2010. The company strongly believes in future growth.
“There are an estimated 180 million dogs in the EU and the US, and the global veterinary market is a business of around €140 billion. With the help of our new Advisory Board, we will support the company in the international market, strengthen our export expertise and our culture of growth,” Kuussaari concludes.
For more information
Olli Kuussaari, President and CEO, +35850 520 2225, olli.kuussaari@vetcare.fi
Vetcare is a Finnish-owned manufacturer, wholesaler and importer of veterinary medicines founded in 1992 by three veterinarians. The Group’s total turnover in 2021 was approximately €39 million.